Deep Science Ventures

#AI #Antibody discovery workflow #Antiverse #Deep Science Ventures

How generative AI is rewriting the rulebook for antibody drug discovery

Dr Kerstin Papenfuss, Deep Science Ventures, and Ben Holland, Antiverse, discuss how generative AI is helping advance antibody discovery.  The therapeutic antibody, once 'the next big thing,' has matured into a cornerstone of modern medicine, standing alongside small molecules as a staple of drug development. Yet, while artificial intelligence (AI) has dramatically… Read More

#Exclusive Content

#Artificial intelligence (AI) #Deep Science Ventures #Drug discovery #Fibrosis

Teaming up to tackle global health crises: Fibrosis

Kerstin Papenfuss, PhD, Director, Pharma, Deep Science Ventures, looks at the unmet need for fibrosis treatments and where drug discovery opportunities lay in terms of treatment and technology. Fibrosis is a complex pathological process characterised by excessive accumulation of extracellular matrix (ECM) components, particularly collagen, in response to chronic tissue… Read More

#Exclusive Content

#Collaboration #Deep Science Ventures #Fibrosis #Finance #General Inception #Therapeutics

Venture partners create fibrosis-focused therapeutics company

Venture studios Deep Science Ventures and General Inception have announced plans to create a company focused on developing novel treatments for fibrosis. Science Ventures and General Inception’s European arm, Igniter Europe, aim to establish a company dedicated to overcoming current bottlenecks in fibrosis therapeutics by developing a novel concept and… Read More

#Business & Investment #News